Numerate Inc., of San Bruno, Calif., entered a research collaboration with Boehringer Ingelheim (Canada) Ltd., of Burlington, Ontario. The collaboration will use Numerate's in silico drug design technology to generate small-molecule drug leads for an undisclosed infectious disease target.